Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs
- PMID: 15206584
- DOI: 10.2131/jts.29.155
Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs
Abstract
In order to clarify the mechanism of the neurotoxicity of 5-FU and/or its masked compounds, we studied the effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on the formation of vacuolar changes in the dog cerebrum, using the dosage of 3.0 mg/kg/day of FBAL-HCl (FBAL x HCl) and 0.03 mg/kg/day of FA-Na (FA x Na), respectively. These 2 compounds were selected because they are the metabolites of 5-FU claimed to be responsible for the neurotoxic effects of 5-FU and/or its masked compounds, and we wanted to confirm their effects. Tegafur-uracil mixture (UFT) was used as a positive control drug for the formation of vacuolar changes in the dog cerebrum. All compounds were orally administered daily for 3 months to beagle dogs. Each study group consisted of 3 males. Neurotoxic signs such as hyperesthesia and/or excitement, as well as convulsions, were observed in both FBAL x HCl and FA x Na groups; these toxic signs were also found in the UFT group. Slight loss of body weight gain and of food consumption was observed in the FBAL x HCl and UFT groups. Neuropathologically, vacuolar changes were detected in several areas of the dog cerebrum following administration of FBAL x HCl, FA x Na or UFT. In terms of morphology, the neuropathological effects of these 2 drugs were very similar to those induced by UFT. In conclusion, we clearly showed that FBAL is one of the main substances that cause neurotoxic signs and neuropathological changes in dogs intoxicated by 5-FU or its masked compounds. Moreover, FA might be considered to be a causative factor in addition to FBAL.
Similar articles
-
Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.Acta Neuropathol. 1990;81(1):66-73. doi: 10.1007/BF00662639. Acta Neuropathol. 1990. PMID: 2128162
-
[Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].Gan To Kagaku Ryoho. 2000 Jun;27(6):885-90. Gan To Kagaku Ryoho. 2000. PMID: 10897216 Japanese.
-
Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture.Acta Neuropathol. 1996 Jul;92(1):8-13. doi: 10.1007/s004010050482. Acta Neuropathol. 1996. PMID: 8811119
-
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].Gan To Kagaku Ryoho. 1998 Feb;25(3):371-84. Gan To Kagaku Ryoho. 1998. PMID: 9492831 Review. Japanese.
-
Uracil-tegafur in gastric carcinoma: a comprehensive review.J Clin Oncol. 1998 Aug;16(8):2877-85. doi: 10.1200/JCO.1998.16.8.2877. J Clin Oncol. 1998. PMID: 9704742 Review.
Cited by
-
The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.Future Oncol. 2016 Sep;12(17):2009-20. doi: 10.2217/fon-2016-0091. Epub 2016 Jun 9. Future Oncol. 2016. PMID: 27279153 Free PMC article. Review.
-
Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.Cancers (Basel). 2020 Jun 21;12(6):1641. doi: 10.3390/cancers12061641. Cancers (Basel). 2020. PMID: 32575843 Free PMC article. Review.
-
Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Clin Pharmacokinet. 2013 Jun;52(6):399-414. doi: 10.1007/s40262-013-0040-2. Clin Pharmacokinet. 2013. PMID: 23420518 Review.
-
Enzymatic carbon-fluorine bond cleavage by human gut microbes.Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2504122122. doi: 10.1073/pnas.2504122122. Epub 2025 Jun 13. Proc Natl Acad Sci U S A. 2025. PMID: 40512801 Free PMC article.
-
Seizures following subconjunctival 5-FU therapy.Graefes Arch Clin Exp Ophthalmol. 2011 Jan;249(1):145-6. doi: 10.1007/s00417-010-1361-6. Epub 2010 Mar 30. Graefes Arch Clin Exp Ophthalmol. 2011. PMID: 20352442 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources